eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course for sponsors - September 2025, Online, from 29 September 2025, 09:00 (CEST) to 30 September 2025, 13:30 (CEST)
Reflection paper on lessons learned from the COVID-19 pandemic: Scientific considerations on non-clinical aspects
We are pleased to announce the release of the EFIM Annual Report 2024.
The report highlights our key achievements, activities, and collaborations over the past year, reflecting EFIM’s continued commitment to advancing internal medicine across Europe.
Read EFIM Annual Report here!
ICH E20 adaptive designs for clinical trials - Scientific guideline
ICH E20 guideline on adaptive designs for clinical trials - Step 2b
Orphan designation: Ramiprilat Treatment of Stargardt's disease, 12/03/2013 Withdrawn
Orphan designation: Adeno-associated virus serotype C102 containing the human GLA gene Treatment of Fabry disease, 13/04/2022 Withdrawn
Orphan designation: octreotide hydrochloride Treatment of acromegaly, 12/06/2009 Withdrawn
Lurasidone product-specific bioequivalence guidance
List of centrally authorised products with safety-related changes to the product information